MT 906 L-3,4-Dihydroxyphenylalanine, [ring-2,5,6-3H]-
|
| (L-DOPA,
[ring-2,5,6-3H]-) |
| 3,4-(OH)2C6H3CH2CH(NH2)COOH |
| Delivered ≥ 96%
pure with dated HPLC radiochromatogram |
| 28mM Ascorbic acid solution under argon |
| > 20 Ci(0.74 TBq)/mmol |
Please
Inquire for Pricing |
|
Vial which protects contents from UV light - shipped on dry ice |
| M.W. 197.2 |
|
This material is pharmaceutically unrefined, and not intended for use in humans, clinical diagnosis,
or data derived from its use to support regulatory filings. |
MT 906M L-3,4-Dihydroxyphenylalanine, [ring-2,5,6-3H]-
|
|
Click
here for Typical
Certificate of Analysis |
| (L-DOPA,
[ring-2,5,6-3H]-) |
| 3,4-(OH)2C6H3CH2CH(NH2)COOH |
| Delivered ≥ 96%
pure with dated HPLC radiochromatogram |
| 28mM Ascorbic acid solution under argon |
| 3-20 Ci(111-740
GBq)/mmol |
Please
Inquire for Pricing |
|
Vial which protects contents from UV light - shipped on dry ice |
| M.W. 197.2 |
|
This material is pharmaceutically unrefined, and not intended for use in humans, clinical diagnosis,
or data derived from its use to support regulatory filings. |